Ascorbic Acid and Thiamine Effect in Septic Shock
- Conditions
- Septic ShockSepsis
- Interventions
- Drug: Normal saline solutionDrug: Combination therapy of vitamin C and thiamine
- Registration Number
- NCT03756220
- Lead Sponsor
- Tae Gun Shin
- Brief Summary
The aim of this study is to evaluate the efficacy of early metabolic resuscitation with combination therapy using vitamin C and thiamine in improving organ function and survival in patients with septic shock.
- Detailed Description
Sepsis is a complex disease involving life-threatening organ dysfunction caused by a dysregulated host response to infection and is still associated with unacceptably high mortality. Sepsis management should be undertaken as a medical emergency and focused on timely intervention, including early identification and treatment of infection through appropriate antimicrobial therapy and source control when applicable as well as reversing hemodynamic instability through fluid resuscitation and vasopressor use if necessary. Despite these supportive therapies, morbidity and mortality have remained high, suggesting the need for adjuvant therapies for inflammatory and oxidative stress in patients with sepsis; however, no agents have been proven to definitely improve survival.
Vitamin C plays a role in mediating inflammation through antioxidant activities and is also important as a cofactor/co-substrate for the synthesis of endogenous adrenaline, cortisol, and vasopressin. Recently, several clinical trials have reported the positive effects of vitamin C on outcomes in sepsis or septic shock. During sepsis, vitamin C prevents neutrophil-induced lipid oxidation and protects against the loss of the endothelial barrier. Early intravenous supplementation is therefore needed to limit loss of microcirculation and oxidation of lipids. Thiamine is also a key cofactor for glucose metabolism, the generation of ATP (adenosine triphosphate), and the production of NADPH. Considering acute consumption in the hypermetabolic state, thiamine supplementation might be a reasonable therapeutic adjunct for patients with sepsis and was added to reduce the risk of renal oxalate crystallization. These findings led to a recent before-and-after study showing that treatment of sepsis with a combination of vitamin C, hydrocortisone, and thiamine prevented organ dysfunction and reduced the mortality rate.
The aim of this study is to evaluate the efficacy of early metabolic resuscitation with combination therapy using vitamin C and thiamine in improving organ function and survival in patients with septic shock.
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- All
- Target Recruitment
- 116
- Adult patients (> 18 years)
- Septic shock: sepsis with persisting hypotension requiring vasopressors to maintain a mean arterial pressure ≥65 mm Hg and a serum lactate level >2 mmol/L despite adequate volume resuscitation. Sepsis is defined as clinically suspected or confirmed infection with acute organ failure identified as an acute change in total SOFA score with 2 points or more.
- Transferred patients from other hospitals after application of vasopressors or mechanical ventilation
- Patients who signed a "Do not attempt resuscitation" order or who had set limitations on invasive care
- Patients who have a terminal, unresponsive illness and survival discharge is not expected (metastatic terminal cancer, etc.)
- Patients who experienced cardiac arrest before enrollment or when death is anticipated within 24 hours despite maximal treatment
- Patients who take more than 1g of Vitamin C per day before enrollment or who take supplemental thiamine
- Pregnant woman
- Known Glucose-6-phosphate dehydrogenase deficiency
- Patients with a history of hypersensitivity to vitamin C or thiamine
- Known Mediterranean anemia
- Known hyperoxaluria
- Known cystinuria
- Acute gout attack
- Known oxalate renal stone
- Patients who meet the inclusion criteria 24 hours after emergency department arrival or when enrollment is delayed more than 24 hours after diagnosis of septic shock
- Inability or refusal of a subject or legal surrogate to give informed consent
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- PARALLEL
- Arm && Interventions
Group Intervention Description Control Normal saline solution Normal Saline Solution Treatment Combination therapy of vitamin C and thiamine Combination therapy of vitamin C and thiamine for 2 days.
- Primary Outcome Measures
Name Time Method Delta Sequential Organ Failure Assessment (SOFA) score Enrollment to 72 hours 72-hour change in SOFA score, which reflected recovery from organ failure (delta SOFA = SOFA at enrollment - SOFA after 72 hours)
- Secondary Outcome Measures
Name Time Method 28-day mortality Day 28 The number of participants who did not survive until Day 28 will be compared between the treatment and the control group
7-day mortality (early death) Day 7 The number of participants who did not survive until Day 7 will be compared between the treatment and the control group
90-day mortality Day 90 The number of participants who did not survive until Day 90 will be compared between the treatment and the control group
Time to death Enrollment to Day 28 Days until death
In-hospital death Up to 12 weeks The number of participants who did not survive at hospital discharge will be compared between the treatment and the control group
Intensive care unit death (ICU) death Up to 12 weeks The number of participants who did not survive at ICU discharge from the first index ICU admission will be compared between the treatment and the control group
Time to Shock reversal Enrollment to Day 14 Days from enrollment to shock reversal until Day 14. Shock reversal is defined as discontinuation of all vasopressors and mean arterial pressure is maintained at 60 mmHg or more for more than 24 hours.
Vasopressor free days Enrollment to Day 14 Days not receiving any vasopressor
Renal replacement therapy (RRT) free days Enrollment to Day 14 Days not receiving Renal replacement therapy
New use of renal replacement therapy (RRT) Up to 12 weeks The number of participants who receive RRT during hospital stay will be compared between the treatment and the control group
New onset or aggravation of acute kidney injury (AKI) Enrollment to Day 14 The number of participants who suffer from new onset or aggravation of AKI will be compared between the treatment and the control group
Length of ICU stay Up to 12 weeks Number of days in the ICU during hospital admission
ICU free day Enrollment to Day 14 Days not being in the ICU
Length of hospital stay Up to 12 weeks Number of days in the hospital during hospital admission
Ventilator free days Enrollment to Day 14 Days not receiving mechanical ventilation
Ventilator duration Up to 12 weeks Days receiving mechanical ventilation during hospital stay
Trial Locations
- Locations (6)
Department of Emergency Medicine, University of Ulsan College of Medicine, Asan Medical Center,
🇰🇷Seoul, Korea, Republic of
Department of Emergency Medicine, Seoul National University College of Medicine,
🇰🇷Seoul, Korea, Republic of
Department of Emergency Medicine, Yonsei University College of Medicine
🇰🇷Seoul, Korea, Republic of
Department of Emergency Medicine, Seoul National University Bundang Hospital,
🇰🇷Seongnam, Gyeonggi-do, Korea, Republic of
Department of Emergency Medicine, Borame Medical Center, Seoul National University, College of Medicine
🇰🇷Seoul, Korea, Republic of
Department of Emergency Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine,
🇰🇷Seoul, Korea, Republic of